Fluid and solute fluctuations during the week are the main drawbacks of conventional hemodialysis (cHD) in patients' outcomes. The aim of our study was to evaluate the influence of every other day hemodialysis (eodHD) on clinical and laboratory parameters and to compare to that of cHD. Eighteen patients on cHD were included in the study. Nine patients (group I) were randomly switched to eodHD, while the rest (group II) remained on their regular cHD. By the end of the study (12 months) we observed a reduction in body weight followed by a parallel reduction in predialysis mean blood pressure by 7 mm Hg in group I (p < 0.05) and the number of antihypertensives. Moreover, a reduction in left ventricular mass and an increment of ejection fraction was observed in group I. Hemoglobin levels remained stable in both groups, but erythropoietin dose was reduced in eodHD group. Dialysis delivered dose (dpKt/V) was higher and urea rebound phenomenon was less in group I. Finally, an improvement in uremia related and postdialysis symptoms was observed in the same group of patients. Our results showed that eodHD improved patients' clinical and biochemical status and therefore might have advantages in patients' outcomes compared with cHD. ASAIO Journal 2009; 55:41-46.
Fluid and solute fluctuations during the week are the main drawbacks of conventional hemodialysis (cHD) in patients' outcomes. The aim of our study was to evaluate the influence of every other day hemodialysis (eodHD) on clinical and laboratory parameters and to compare to that of cHD. Eighteen patients on cHD were included in the study. Nine patients (group I) were randomly switched to eodHD, while the rest (group II) remained on their regular cHD. By the end of the study (12 months) we observed a reduction in body weight followed by a parallel reduction in predialysis mean blood pressure by 7 mm Hg in group I (p < 0.05) and the number of antihypertensives. Moreover, a reduction in left ventricular mass and an increment of ejection fraction was observed in group I. Hemoglobin levels remained stable in both groups, but erythropoietin dose was reduced in eodHD group. Dialysis delivered dose (dpKt/V) was higher and urea rebound phenomenon was less in group I. Finally, an improvement in uremia related and postdialysis symptoms was observed in the same group of patients. Our results showed that eodHD improved patients' clinical and biochemical status and therefore might have advantages in patients' outcomes compared with cHD. ASAIO Journal 2009; 55:41-46.
The "short dialysis schedule" (4 hours ϫ 3 times/wk) or conventional hemodialysis (cHD), introduced by Cambi in 1975 , is the gold standard dialysis time schedule all over the world. 1 However, fluid and solute fluctuations during the week and the decreasing efficiency during the course of dialysis sessions are, among others, the main drawbacks of the cHD schedule. [2] [3] [4] The decrease in efficiency during the course of dialysis sessions is due not only to solute disequilibrium between tissue and intravascular compartments, but also to the fact that, the first-order kinetic process of solute removal itself makes dialysis sessions more ineffective because of an exponential decrease in blood solute concentration. 2 However, the large fluid fluctuations occurring during the thrice weekly dialysis schedule, as a result of large interdialytic fluid gain, lead to increased cellular and vascular stress. 5 The large interdialytic fluid gain might contribute to the development of high arterial blood pressure in these patients which is an established risk factor for left ventricular hypertrophy, diastolic dysfunction and congestive heart failure, ventricular arrhythmias, and atherosclerosis. 6 Morbidity and mortality mainly due to cardiovascular disease continue to be unacceptably high in the hemodialysis (HD) population, despite ongoing technical advances in HD therapy and undiminished nephrologists' efforts in providing adequate solute clearance and achieving best control of dry body weight. 6 Thus, interest in frequent HD regimes seems to be growing worldwide. High efficiency short duration daily HD and long slow daily or nocturnal HD regimes are the two most common forms in use to override the above-mentioned drawbacks of cHD. 7, 8 However, although, few studies have reported remarkable patient improvement using daily HD, the question whether it is superior to cHD with respect to patient outcome and survival has not been definitely proven yet. Moreover, many methodological, clinical, economical, and organizational concerns limit its broad applicability in every day practice. 9 Considering cHD drawbacks and daily HD limitations, we conducted a prospective study to evaluate the influence of every other day HD schedule (eodHD, equal intervals of 44 h between HD sessions) on clinical, echocardiographic, biochemical and HD delivered dose parameters and compare them with patients on cHD (2 ϫ 44 h and 1 ϫ 72 h interval between HD sessions).
Materials and Methods

Study Population
All adult patients of our hemodialysis unit who were stable for the last 6 months were informed of the study. Eighteen patients agreed to participate and consented. These patients were ordered alphabetically and odd numbers were included in the eodHD group I (nine patients) while the rest (group II) remained on their cHD schedule. Patient's demographic characteristics and primary renal diseases are shown in Table 1 . All patients had residual diuresis Ͻ100 ml/d and were dialysed through an arteriovenous fistula (16 patients) or PTEE graft (2 patients). Vascular access recirculation was estimated in all patients by slow flow method and was Ͻ5%. 10 Exclusion criteria were diabetes mellitus, known uncured malignancy, active inflammation at the time of the enrollment, liver and heart (stage IV NYHA) failure, malnutrition, medications affecting urea metabolism such as corticosteroids. The study was approved by the Hospital Ethics Board.
Study Protocol
The duration of this prospective study was 12 months. All patients were dialysed in the morning. Prescribed HD regimes per dialysis were similar in both groups and are given in Table  2 . All patients were kept on the same dialyzer during the 12 month study period. They were closely monitored during HD and all events and causes for dialysis alarms were recorded. Standing and supine arterial blood pressure (systolic and diastolic) was measured at the beginning and at the end of HD sessions, while mean arterial blood pressure (MAP) was calculated. Blood pressure medications (BPM) adjustments were done throughout the study period to achieve blood pressure levels Ͻ135/85 mm Hg and to avoid hypotension. 11 Scaled body weight (BW) was recorded pre-and post HD.
Intravenous postdialysis recombinant human erythropoietin (rhuEpo) dose was adjusted to maintain a target of hemoglobin levels between 11 and 13 g/dl according to K/DOQI guidelines and iron supplements were prescribed accordingly as well. 12 Vitamin-D dose was adjusted to achieve intact parathormone (iPTH) therapeutic levels according to K/DOQI guidelines. 13 
Assessments
A monthly predialysis blood sample was taken after a 12 h overnight fast from the dialyzer inflow line to estimate the following parameters: a) hematological parameters [Ht, Hb, serum iron (sIron) and ferritin (sFerritin)], b) biochemical parameters [serum urea (sUrea), creatinine (sCreat), inorganic phosphorus (sPO 4 Ϫ ), total calcium (sCa 2ϩ ), magnesium (sMg 2ϩ ), albumin (sAlb), and iPTH].
Every 3 months, two extra blood samples were obtained for estimation of urea rebound phenomenon and dialysis delivered dose (Kt/Vurea) index: 1) At the end of the HD session for estimation of sUrea, sCreat, sPO 4 Ϫ and sAlb; 2) Sixty minutes after HD session for repeat estimation of sUrea, sCreat, sPO 4 Ϫ , and sAlb. The timing of sampling was the 2nd HD session of the first week of each month (Wednesday or Thursday) for group I, and the 2nd or 3rd HD session of the first week of each month for group II.
Both sPO 4 Ϫ and sMg 2ϩ were measured by a photometric UV test (Olympus 600 -Olympus Diagnostica GmbH, Ireland). Serum albumin was measured by a photometric-BCG method (Olympus 600 -Olympus Diagnostica GmbH Ireland), while iPTH by Chemiluninescent Immunoassay (Immulite 2000, Diagnostic Product Corporation).
Moreover, concentrations of intracellular inorganic phosphorus ([PO 4 Ϫ ]i) and 2.3 DPG enzyme ([2.3DPG]i) were assessed by a previous established method 14 at the beginning and at the end of the study.
Calculations
Estimations of urea, creatinine, and phosphorus rebound phenomenon, Kt/Vurea index and protein catabolic rate (PCR) index were done by using the following equations:
Rebound (R) for urea, creatinine and phosphorus was calculated by the equation 15 :
where: C Td eq (mg/dl) ϭ serum urea, creatinine and phosphorus concentration 60Ј after HD session C Td (mg/dl) ϭ serum urea, creatinine and phosphorus concentration at the end of HD session Dialysis delivered dose via the Kt/Vurea index was calculated using double pool (dp) equation 16 : dp Kt/Vurea ϭ sp Kt/Vurea ͫ 1 Ϫ
0.6
Td/60 ͬ ϩ 0.03 and Where: Td (min) ϭ duration of HD session and
Where: R ϭ C Td /Co Co (mg/dl) ϭ serum urea, creatinine and phosphorus concentration before HD session t (hours) ϭ duration of HD session UF (L) ϭ ultrafiltration BW (kg) ϭ dry body weight (post dialysis) Protein intake was estimated from PCR index using Garred's equation 17 : No food and fluid intake was permitted during HD sessions and for 60 min after HD was terminated.
Echocardiography
In all patients, a trans-thoracic echocardiography was performed on an interdialytic day before the initiation and after the end of the study period. 18 M-mode and two-dimensional images (2-D) as well as color-flow Doppler recordings were obtained (HDI 5000, Phillips). Left ventricular mass (LVM) was calculated from end-diastolic left ventricular dimensions using the Devereux formula. 19 Left ventricular hypertrophy was defined as a LVM Ͼ125 g/m 2 for male and Ͼ100 g/m 2 for female. 20 Left ventricular ejection fraction (LVEF) was measured by the quantitative 2-D biplane volumetric Simpson formula. Doppler measurements were used to assess diastolic cardiac function and the following parameters were defined: peak velocities of mitral inflow filling during early (E) and late (atrial filling: A), E/A ratio and deceleration time (DT).
Statistical Analysis
Analyses were conducted using SPSS (version 11.5, SPSS, Inc, Chicago, IL). Data are reported as mean values Ϯ standard deviations. Comparison between cHD and eodHD groups was made using the paired, two tailed Student's t test. Changes were considered statistically significant for values Ͻ0.05.
Results
All patients completed the study and no death from any cause occurred in either group. At the end of the study, group I showed a significant reduction in BW (p Ͻ 0.05) compared to group II where it remained almost unchanged ( Table 3) . Also, we observed a significant reduction in predialysis standing and supine MAP by 9 and 7 mm Hg in group I patients respectively (p Ͻ 0.05) (Figure 1) followed by a parallel reduction in the number of BPM (p Ͻ 0.05) ( Table 3 ), compared to group II. Furthermore, at the end of the study, eodHD patients exhibited improved cardiac geometry and function, indicated by a significant reduction in LVM (p Ͻ 0.05) along with an increase in LVEF (p Ͻ 0.001) ( Table 4 ). In contrast, in group II, LVM remained unchanged and LVEF deteriorated (p Ͻ 0.05). Doppler measurements did not differ between the two groups neither at the start nor the end of the study.
Regarding solute clearance, predialysis serum urea and creatinine concentrations were significantly lower after 12 months of treatment in group I (p Ͻ 0.05) compared to group II (Table 3) . Furthermore, in group I, we observed a significant reduction of sUrea, sCreat and sPO 4 Ϫ rebound phenomenon (p Ͻ 0.05) compared to group II (p ϭ NS) ( Table 3) . With regard to dialysis adequacy, although dpKt/Vurea per session remained almost unchanged in both groups, the calculated monthly dpKt/Vurea index (dpKt/Vurea per session multiplied by the number of HD sessions in a month's time) was significantly higher in group I (p Ͻ 0.05), whereas there was no significant change in group II (data not shown).
Serum phosphorus and iPTH levels were lower at the end of the study in group I patients compared to baseline values (p Ͻ 0.05) while remained unchanged in group II ( Table 3) . Regarding protein intake, nPCR was better in group I patients (p Ͻ 0.05) compared to group II (Table 3 ) with a slight increase of sAlb in group I (4.12 Ϯ 0.2 vs. 3.77 Ϯ 0.4 g/dl, p ϭ NS).
Hemoglobin and hematocrit levels remained unchanged in both groups during the study period. Nevertheless, we observed a significant reduction in the weekly rhuEpo dose in group I (p Ͻ 0.05) while there was no change in group II rhuEpo dose ( Table 5) .
Finally, eodHD patients reported an improvement in uremia related and postdialysis symptoms once they were on the eodHD program for two or more months in comparison to group II patients.
Discussion
The results of this prospective study, showed that eodHD schedule had some advantages compared to cHD regime, namely, better control of arterial blood pressure with less antihyperpentensives, improvement of cardiac function, better dialysis adequacy, better control of bone metabolism and a possible improvement of nutrition status. Moreover, there was a positive effect on patients' overall feeling of well-being, uremia and dialysis related symptoms.
Predialysis arterial blood pressure decreased significantly in our patients on eodHD, and this reduction was already apparent after the first 12 weeks of treatment. More frequent ultrafiltration of less gained intradialytic volume resulted in a reduction in BW and more stable dialysis session with eodHD. These results are comparable to findings from trials using short daily HD and slow nocturnal HD. 5, [21] [22] [23] The beneficial effect of eodHD on BP could not be explained only from better body volume status, but one may speculate that smaller fluctuation of fluid volume may have an effect on the activation of vasoconstrictive factors and sympathetic activity. The latter can be supported by the results of Chan et al. who found that patients treated by daily nocturnal HD had lower peripheral vascular resistance and lower circulating neurohumoral factors, such as noreprenephrine. 23 Importantly, LVM decreased significantly in our eodHD patients, which is in agreement with results from other studies applying more frequent HD regimes. 24 LVH along with other factors, such as anemia, hypertension, fluid overload, hyperphosphatemia, are known independent risk factors for the increased cardiovascular burden among dialysis population and reduction of LVM and arterial blood pressure might have beneficial effect on patients' cardiovascular outcome. 25 The rationale of more frequent HD includes increased efficiency of small solute clearance by spending more time dialyzing against higher (postrebound) solute concentrations. According to our results small molecular weight solute clearance was improved in eodHD by increasing monthly delivered dpKt/Vurea. Similar results have previously been reported by other investigators who applied daily programs. 5, 26 Improved urea clearance, as measured by dpKt/Vurea has been shown to be associated with improved nPCR index, better nutritional status and improved patients' outcome. 27, 28 Some centers have reported an increase in nPCR, dry weight and caloric intake in patients who were 6 times per week on cHD. 7,8,29 -31 We also observed that from patients on eodHD nPCR was increased and uremic environment was improved, as expressed by lower predialysis sUrea and sCreat concentrations in the extracellular compartment and lower rebound of urea, creatinine, and phosphorus in the intracellular compartment.
A better control of hyperphosphatemia and secondary hyperpahrathyroidism was observed at the end of the study in patients treated by eodHD compared to patients on cHD. Although, phosphorus mass removal was not measured, the lower predialysis sPO 4 Ϫ concentration accompanied by an increase in nPCR advocated less phosphorus accumulation in the body. Hyperphosphatemia along with factors such as elevated levels of parathyroid hormone, tissue alkalinity, hypercalcemia, and particularly an elevated Ca 2ϩ ϫ PO 4 Ϫ product promote cardiovascular calcification. 32, 33 The improvement of balance in Ca 2ϩ and PO 4 Ϫ metabolism is achieved by increasing delivered dialysis dose. However, more frequent dialysis sessions may improve vitamin D metabolism which contributes to improved control of Ca 2ϩ and PO 4 Ϫ metabolism. 34 At the end of the study, we did not observe any significant alteration on [PO 4 Ϫ ]i levels and [2.3DPG]i enzyme in either group. A possible explanation could be that even in eodHD patients, the cellular energy status remained almost unchanged preserving the existent balance between inorganic and organic intracellular phosphorus. At this point, it is worth mentioning the higher values of [PO 4 Ϫ ]i compared to serum in both groups. This interesting finding of our study differs from the results in the study of Bevington et al., who reported lower levels of [PO 4 Ϫ ]i in comparison to plasma levels in patients receiving regular hemodialysis. 35 Although metabolic acidosis is a potent stimulus for intracellular inorganic phosphorous generation, mainly through hydrolysis of [2.3DPG]i, other factors related to current hemodialysis policies such as the different dialysate composition (bicarbonate versus acetate), widely usage of erythropoietin which causes the transfer of phosphorous from extra to intracellular compartment 36 and the prescription of newer phosphate binders which leads to better control of hyperphosphatemia, might contribute to a higher [PO 4 Ϫ ]i concentration in our patients. More frequent HD sessions and increased delivered dialysis dose have been associated with less need for exogenous erythropoietin. Our results are in agreement with previous studies. 7,28 -31,37 However, recently published results from the London Daily Nocturnal Hemodialysis Study failed to show any significant reduction in erythropoietin utilization. 38 Since uremic toxins might directly inhibit erythropoietin synthesis or affect O 2 receptors their increased removal during more frequent HD and the improvement of the uremic environment, 5, 39 could partly explain our result as well.
In our experience, eodHD proved a safe program with no complications for our patients. However, our study had a number of limitations such as, small number of patients and more frequent assessments of eodHD group. Since, it could not have been blind, nurses and doctors tried to pay the same attention and treat equally both groups. Moreover, the main disadvantage of eodHD schedule appears to be higher cost mainly due to: a) dialysis consumables cost and b) patients' transportation. It has been proposed that decreased hospitalization rate along with reduced erythropoietin administration and less BPM may outbalance the additional cost of eodHD. 9, 40, 41 However eodHD schedule seems more flexible and easier to apply in comparison with daily schedules such as short daily and long slow nocturnal daily HD which might of course be superior to eodHD as have already been proven to conventional HD regarding patients' outcome. 9 In conclusion, the results of our pilot study show that eodHD might be better than cHD in controlling BP, BW and certain clinical and biochemical parameters by providing better dialysis adequacy. By overriding some cHD disadvantages and daily HD practical limitations, eodHD program could be implemented in a larger scale as an alternative promising method. However, successful implementation of such a program presumes a good relationship between patients and renal team, available infrastructure and governmental financial support.
